MDCX · XBRL financial data
Medicus Pharma financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (MDCX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|
| Research and development | 3,528 | 7,721 |
| General and administrative | 7,653 | 17,920 |
| Total operating expenses | 11,181 | 34,359 |
| Operating income (loss) | (11,181) | (34,359) |
| Other income (expense) | 25 | (1,085) |
| Income tax expense (benefit) | 0 | 0 |
| Net income (loss) | (11,156) | (47,282) |
| Earnings per share, basic USD per share | (1.16) | (2.74) |
| Earnings per share, diluted USD per share | (1.16) | (2.74) |
| Weighted average shares, basic thousands of shares | 9,619 | 17,284 |
| Weighted average shares, diluted thousands of shares | 9,619 | 17,284 |
- † Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (MDCX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 4,164 | 8,705 |
| Total current assets | 5,378 | 9,891 |
| Right-of-use asset | 269 | 171 |
| Total assets | 5,647 | 10,061 |
| Accounts payable | 1,285 | 3,435 |
| Total current liabilities | 2,306 | 9,938 |
| Lease liability, non-current | 206 | 60 |
| Total liabilities | 2,512 | 10,024 |
| Accumulated deficit | (28,904) | (64,348) |
| Total stockholders' equity | 3,135 | (68) |
| Total liabilities and equity | 5,647 | 10,061 |
| Common shares outstanding (cover page) thousands of shares | 13,415 | 39,362 |
- † Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (MDCX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (11,156) | (47,282) |
| Stock-based compensation | 713 | 1,512 |
| Net cash from operating activities | (10,247) | (22,777) |
| Net cash from investing activities | 0 | (4,619) |
| Proceeds from issuing common stock | 5,470 | 9,790 |
| Net cash from financing activities | 12,692 | 31,940 |
| Net change in cash | 2,445 | 4,541 |
- † Share count changed about 3x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Medicus Pharma | 15,174 | not reported | (6,983)* | 63.2M | 2.2 quarters | 10-QJun 30, 2026 |
| Champions Oncology | 4,358 | 15,232 | (492) | 13.9M | 8.0 quarters | 10-QJul 31, 2026 |
| OnKure Therapeutics | 166,502 | not reported | (10,354)* | 40.5M | 17.0 quarters | 10-QJun 30, 2026 |
| Rockwell Medical | 10,519 | not reported | 2,080* | 4.0M | — | 10-QJun 30, 2026 |
| Cumberland Pharmaceuticals | 3,862 | 166 | 169* | 15.0M | — | 10-QJun 30, 2026 |
| ProMIS Neurosciences | 53,429 | not reported | (10,385)* | 9.0M | 5.1 quarters | 10-QJun 30, 2026 |
| Outlook Therapeutics | 11,242 | not reported | (21,011)* | 243.4M | 0.5 quarters | 10-QJun 30, 2026 |
| Tempest Therapeutics | 779 | not reported | (2,779)* | 16.0M | 0.3 quarters | 10-QJun 30, 2026 |
| Provectus Biopharmaceuticals | 1,157 | not reported | (358)* | 420.3M | 3.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.